TOKYO — Japanese trading house Sumitomo Corp. is partnering with U.S. nuclear fusion startup Shine Technologies to enter the Asian cancer treatment field, using the American company’s strengths in radioisotopes to secure profits while gaining a foothold in a next-generation energy sector.
Shine, founded in 2005, is developing fusion power generation technology using deuterium and tritium. As part of that development, it has the technology to safely generate lutetium-177, a radioisotope effective in cancer treatment.
